Patients are therefore advised to drink alcohol in moderation
However, the Northern Africa and Middle East (MENA) region and Asia are experiencing rapid growth in the MASLD risk factors of obesity and T2D [33,34]
Geriatric population increasingly require therapies that offer glycemic control, weight reduction benefits, and broader cardiometabolic support
Providers must look at these factors before starting therapy and adjust plans as needed
Lilly showed in recently announced clinical trial results that patients who switched to orforglipron after losing weight on either Wegovy or Zepbound regained less weight than participants who switched to a placebo
While microdosing programs are not intended for significant weight loss, program participants may experience reduced appetite and cravings, leading to gradual, sustained weight management